ROCKVILLE, Md. (AP) -- CPL Biologicals Pvt. Ltd., a joint venture between biotechnology company Novavax Inc. and Cadila Pharmaceuticals Ltd., said Wednesday that it is building a new flu vaccine manufacturing plant in India.
The 25,000 square foot facility is targeted to be running within four months, with 60 million vaccines doses expected to be prepared each year when operating at full capacity.
The plant, which is being paid for by Cadila, will also make other vaccines developed by CPL, based on Novavax technology.
